Tumefactive demyelination: An approach to diagnosis and management

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 9, 2013, Pages 1047-1053

  Hardy, Todd A ^a   Chataway, Jeremy ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FINGOLIMOD; FLUORODEOXYGLUCOSE; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; RITUXIMAB;

BRAIN BIOPSY; BRAIN DAMAGE; CEREBRAL LEUKODYSTROPHY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETINA DISEASE; REVIEW; TREATMENT DURATION; TUMEFACTIVE DEMYELINATION; UNSPECIFIED SIDE EFFECT;

EID: 84881557268     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304498     Document Type: Review

References (61)

1. Ciccarelli O, Miller DH. Magnetic resonance imaging in multiple sclerosis. Pract Neurol 2002;2:103-12.
2. Poser S, Lüer W, Bruhn H, et al. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 1992;86:579-85. (Pubitemid 23003656)
3. Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008;131 (Pt 7):1759-75. (Pubitemid 351957454)
4. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 2009;31:439-53.
5. Xia L, Lin S, Wang ZC, et al. Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev 2009;32:171-9.
6. Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler 2012;18:1448-53.
7. Masdeu JC, Drayer BP, Anderson RE, et al. Multiple sclerosis-when and how to image. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000;215(Suppl):547-62.
8. He J, Grossman RI, Ge Y, et al. Enhancing patterns in multiple sclerosis: evolution and persistence. AJNR Am J Neuroradiol 2001;22:664-9. (Pubitemid 32318693)
9. Kim DS, Na DG, Kim KH, et al. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 2009;251:467-75.
10. Kiriyama T, Kataoka H, Taoka T, et al. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 2011;21: e69-77.
11. Given CA II, Stevens BS, Lee C. The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 2004;182:195-9. (Pubitemid 38017742)
12. Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007;28:272-7. (Pubitemid 46281044)
13. Butteriss DJ, Ismail A, Ellison DW, et al. Use of serial proton magnetic resonance spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient with multiple sclerosis. Br J Radiol 2003;76:662-5.
14. Schiepers C, Van Hecke P, Vandenberghe R, et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 1997;3:8-17. (Pubitemid 27234858)
15. Takenaka S, Shinoda J, Asano Y, et al. Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11) C-choline-, and (18)F-fluorodeoxyglucose-PET. Brain Tumor Pathol 2011;28:229-38.
16. Rosenfeld SS, Hoffman JM, Coleman RE, et al. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992;33:532-6.
17. Alderson L, Fetell MR, Sisti M, et al. Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry 1996;60:102-5. (Pubitemid 26012277)
18. Bromberg JE, Siemers MD, Taphoorn MJ. Is a "vanishing tumor" always a lymphoma? Neurology 2002;59:762-4.
19. Okita Y, Narita Y, Miyakita Y, et al. Long-term follow-up of vanishing tumors in the brain: how should a lesion mimicking primary CNS lymphoma be managed? Clin Neurol Neurosurg 2012;114:1217-21.
20. Ng S, Butzkueven H, Kalnins R, et al. Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. J Clin Neurosci 2007;14:1126-9. (Pubitemid 47588932)
21. Kürtüncü M, Tüzün E, Durmuş H, et al. Primary cerebral lymphoma with a 5-year remission to single-agent corticosteroids. Leuk Lymphoma 2009;50:1552-3.
22. Roemer SF, Scheithauer BW, Varnavas GG, et al. Tumefactive demyelination and glioblastoma: a rare collision lesion. Clin Neuropathol 2011;30:186-91.
23. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993;33:18-27. (Pubitemid 23009905)
24. Wattamwar PR, Baheti NN, Kesavadas C, et al. Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event. J Neurol Sci 2010;297:29-35.
25. Wood DD, Bilbao JM, O'Connors P, et al. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996;40:18-24. (Pubitemid 26250138)
26. Kadhim H, De Prez C, Gazagnes MD, et al. In situ cytokine immune responses in acute disseminated encephalomyelitis: insights into pathophysiologic mechanisms. Hum Pathol 2003;34:293-7. (Pubitemid 36356685)
27. Bennett DL, McCabe DJ, Stevens JM, et al. Tumefactive neuro-Behcet disease. Neurology 2004;63:709.
28. Sanahuja J, Ordoñez-Palau S, Begué R, et al. Primary Sjögren Syndrome with tumefactive central nervous system involvement. AJNR Am J Neuroradiol 2008;29:1878-9.
29. Uriel A, Stow R, Johnson L, et al. Tumefactive demyelination-an unusual neurological presentation of HIV. Clin Infect Dis 2010;51:1217-20.
30. Kiriyama T, Kataoka H, Kasai T, et al. Negative association of Epstein-Barr virus or herpes simplex virus-1 with tumefactive central nervous system inflammatory demyelinating disease. J Neurovirol 2010;16:466-71.
31. Ikeda K, Ito H, Hidaka T, et al. Repeated non-enhancing tumefactive lesions in a patient with a neuromyelitis optica spectrum disorder. Intern Med 2011;50:1061-4.
32. Verma R, Arya K. Tumefactive demyelination associated with systemic lupus erythematosus. BMJ Case Rep 2012. pii: bcr0220125743. doi: 10.1136/bcr.02. 2012.5743.
33. Kim SH, Kim W, Lee KW, et al. Tumefactive demyelination, an uncommon form of tacrolimus neurotoxicity. Neurology 2011;76:672-4.
34. Häne A, Bargetzi M, Hewer E, et al. Recurrent tumefactive demyelination without evidence of multiple sclerosis or brain tumour. J Neurol 2011;258:318-320.
35. Richards A, van den Maagdenberg AM, Jen JC, et al. C-terminal truncations in human 30-50 DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007;39:1068-70. (Pubitemid 47340644)
36. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997;49:1322-30. (Pubitemid 27495637)
37. Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 30-50 DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007;39:1065-7. (Pubitemid 47340647)
38. Selkirk SM, Shi J. Relapsing-remitting tumefactive multiple sclerosis. Mult Scler 2005;11:731-4. (Pubitemid 41685148)
39. Dastgir J, DiMario FJ Jr. Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal. J Child Neurol 2009;24:431-7.
40. Seifert CL, Wegner C, Sprenger T, et al. Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response. Mult Scler 2012;18:1045-9.
41. Mao-Draayer Y, Braff S, Pendlebury W, et al. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology 2002;59:1074-7.
42. Jaffe SL, Minagar A. Demyelinating pseudotumor. Arch Neurol 2005;62:1466-7. (Pubitemid 41352066)
43. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-86.
44. Fan X, Mahta A, De Jager PL, et al. Rituximab for tumefactive inflammatory demyelination: a case report. Clin Neurol Neurosurg 2012;114:1326-8.
45. Haupts MR, Schimrigk SK, Brune N, et al. Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol 2008;255:1272-3.
46. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
47. Comi G. Multiple sclerosis: pseudotumoral forms. Neurol Sci 2004;25(Suppl 4): S374-9. (Pubitemid 39600436)
48. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012;11:157-69.
49. Visser F, Wattjes MP, Pouwels PJ, et al. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012;79:2000-3.
50. Nealon N. Severe multiple sclerosis relapse on Fingolimod. Risk management for disease-modifying treatments 1. 2011. 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. 19.10.2011-22.10.2011.
51. Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?. Neurology 2012;78:928-30.
52. Jander S, Turowski B, Kieseier BC, et al. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012;18:1650-2.
53. Leypoldt F, Münchau A, Moeller F, et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009;72:1022-4.
54. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113-15.
55. Berger JR. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. Mult Scler 2008;14:708-10. (Pubitemid 351954417)
56. Twyman C, Berger JR. A giant MS plaque mimicking PML during natalizumab treatment. J Neurol Sci 2010;291:110-13.
57. Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012;18:108-12.
58. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001;132:463-71.
59. European S, Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
60. Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002;15:257-66. (Pubitemid 34596887)
61. Hayashi T, Kumabe T, Jokura H, et al. Inflammatory demyelinating disease mimicking malignant glioma. J Nucl Med 2003;44:565-9. (Pubitemid 39663424)